...first biosimilar win in EU The European Commission approved Zercepac from Accord Healthcare Ltd. and Shanghai Henlius Biotech Inc....
...and Co. Mirati Therapeutics Inc. Amgen Inc. Merck & Co. U.S. Food and Drug Administration (FDA) Truvian Sciences Inc. Ascletis Pharma Inc. Shanghai Henlius Biotech Inc. Accord...

...AG (see “Alliance Advancing Unbranded Hyperimmune Globulin Product” ). Chinese trio join to develop antibody Shanghai Henlius Biotech Inc....
...at https://www.biocentury.com/coronavirus . Elizabeth S. Eaton, Staff Writer remdesivir, GS-5734 Gilead Sciences Inc. CSL Ltd. Takeda Pharmaceutical Co. Ltd. ADMA Biologics Inc. Shanghai Henlius Biotech Inc. covid-19 cov19count cov19count...

...first, the number of listings nearly doubled, despite a four-month lapse in new listings midyear. Shanghai Henlius Biotech Inc....

...2019 listings included CStone Pharmaceuticals Co. Ltd. (HKEX:2616), CanSino Biologics Inc. (HKEX:6185), Mabpharm Ltd. (HKEX:2181), Shanghai Henlius Biotech Inc....

...NASDAQ:HCM) said it would wait for better market conditions before moving forward with its application. Shanghai Henlius Biotech Inc....

...Corp. (KOSDAQ:244460) 09/20/19 $25.4 $234.5 $218.3 -7% Exagen Inc. (NASDAQ:XGN) 09/18/19 $58.0 $168.5 $186.4 11% Shanghai Henlius Biotech Inc....

...of its proposed range. Parent company Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) said Shanghai Henlius Biotech Inc....
...development through IND submission to Phase III testing in combination with other agents. Hongjiang Li, Staff Writer Shanghai Henlius Biotech Inc. Programmed...

...Phase III testing for desmoid tumors. Hong Kong IPO could give Shanghai Henlius $3.7B valuation Shanghai Henlius Biotech Inc....
...June by Domain, Jean-Philippe Herbeuval, Kurma Partners, Idinvest Partners and Erganeo. BioCentury Staff 10x Genomics Inc. Fate Therapeutics Inc. Shanghai Henlius Biotech Inc. Kurma...

...Exchanges and Clearing Ltd., which operates the exchange. Shanghai Henlius refiles for Hong Kong IPO Shanghai Henlius Biotech Inc....
...of Oxford. A Phase I trial is slated for 2020. BioCentury Staff ADC Therapeutics S.A. Genmab A/S GNS Healthcare Inc. Shanghai Henlius Biotech Inc. SinoMab...

...Wave" ). Four other companies have active applications for listing on the biotech chapter including Shanghai Henlius Biotech Inc....